Research / Brain / Drugs / Drug / Health / Microbiology / Boston / Boston blog main / Boston top stories / National blog main / New York blog main / New York top stories / San Francisco blog main / San Francisco top stories / AbbVie / Autism / Axial Biotherapeutics / B. fragilis / California Institute of Technology / Columbia University / David Donabedian / deals / Domain Associates / GlaxoSmithKline / James Blair / Kallyope / Life Sciences / Longwood Fund / Michelle Dipp / Microbiome / Nancy Thornberry / Parkinson's Disease / Sarkis Mazmanian / seres Therapeutics / startups / VC

With $19M, Axial Becomes Latest Startup to Target Gut-Brain Connection

Posted on: Nov 30, 2016   |   Posted by: Biotech Mag

With $19M, Axial Becomes Latest Startup to Target Gut-Brain Connection

We're still a long way from understanding how the trillions of bacteria that live in and on our bodies, known collectively as the human microbiome, affect our health and...

Continue reading ...